LB Pharmaceuticals, a late-stage biopharmaceutical company focused on neuropsychiatric disorders, announced that CEO Heather Turner will present at the 25th Annual Needham Virtual Healthcare Conference on April 16, 2026. The company is developing LB-102, a potential first benzamide antipsychotic drug in the U.S. for conditions like schizophrenia and bipolar depression. This presentation highlights LB Pharmaceuticals' progress in late-stage development, with LB-102 showing promise as a new treatment option. Investors can watch the live webcast on the company’s website, with a replay available afterward.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Wendy's is running a $1 promotion on small Classic Chocolate or Vanilla Frosty from July 20 to August 23, with early access for Wendy's Rewards members on July 19 in celebration of National Ice Cream Day. The offer is redeemable via the Wendy's app a...
Dyadic International has expanded its bio-industrial pipeline with a new proprietary enzyme program focused on advanced cellulose processing, building on the success of its EN3ZYME™ product. This initiative leverages Dyadic's Dapibus™ platform to str...
Forum Markets has acquired a commercial aircraft engine for about $12 million, increasing its aviation portfolio to four engines leased to major U.S. airlines. The engine, a widely used CFM56-7B model, is already generating revenue under a long-term ...
The award-winning faith-based film 'Our Crossroads,' based on a true story of a young couple caring for orphaned siblings in 1969 Ohio, premiered exclusively on the Angel streaming platform on July 16, 2026. The film, which won Best Faith/Family Feat...
